N Gopalakrishna Iyer1,2, Snjezana Dogan3, Frank Palmer4, Rahmatullah Rahmati5, Iain J Nixon4, Nancy Lee6, Snehal G Patel4, Jatin P Shah4, Ian Ganly4. 1. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ganlyi@mskcc.org. 2. Singhealth/Duke-NUS Head and Neck Centre, National Cancer Centre, Singapore, Singapore. ganlyi@mskcc.org. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, NY, USA. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Oropharyngeal cancers (OPC) secondary to human papillomavirus (HPV) infections likely represent a completely different disease compared with conventional head and neck cancers. Our objective was to analyze a surgically treated cohort to determine predictors of outcome in HPV-positive versus HPV-negative patients. METHODS: HPV positivity was inferred based on p16-immunohistochemistry. Data was available for 201 patients with OPC treated with surgical resection with/without adjuvant radiotherapy between 1985 and 2005. Subsite distribution was: 66 (33 %) tonsil, 46 (23 %) soft palate, and 89 (44 %) tongue base. Patients were classified into low-, intermediate-, and high-risk groups based on p16 status and smoking history. Outcomes stratified by p16 status and risk groups were determined by the Kaplan-Meier method. Factors predictive of outcome were determined by univariate and multivariate analyses. RESULTS: In this cohort, 30 % had locally advanced disease (pT3/T4) and 71 % had nodal metastasis. The 5-year overall (OS), disease-specific, and recurrence-free survival rates were 60, 76, and 66 %, respectively. There were 22 % low-, 34 % intermediate-, and 44 % high-risk patients. Patients who were p16-positive had better survival compared with p16-negative (OS, 74 vs. 44 %; p < .001). Similarly, low-risk group patients had a better survival compared with intermediate- and high-risk groups (OS, 76, 68, 45 %, respectively, p < .001). Independent predictors of survival in p16-negative patients included margin status, lymphovascular invasion, pN status, and extracapsular spread. In contrast, none of these were predictive in p16-positive patients. CONCLUSIONS: Surgically treated patients with p16-positive OPC have superior survival compared with p16-negative patients. Outcomes in p16-positive and p16-negative OPC are determined by different prognostic factors supporting the notion that these are very different diseases. These should be incorporated into future clinical trials design.
BACKGROUND:Oropharyngeal cancers (OPC) secondary to human papillomavirus (HPV) infections likely represent a completely different disease compared with conventional head and neck cancers. Our objective was to analyze a surgically treated cohort to determine predictors of outcome in HPV-positive versus HPV-negative patients. METHODS:HPV positivity was inferred based on p16-immunohistochemistry. Data was available for 201 patients with OPC treated with surgical resection with/without adjuvant radiotherapy between 1985 and 2005. Subsite distribution was: 66 (33 %) tonsil, 46 (23 %) soft palate, and 89 (44 %) tongue base. Patients were classified into low-, intermediate-, and high-risk groups based on p16 status and smoking history. Outcomes stratified by p16 status and risk groups were determined by the Kaplan-Meier method. Factors predictive of outcome were determined by univariate and multivariate analyses. RESULTS: In this cohort, 30 % had locally advanced disease (pT3/T4) and 71 % had nodal metastasis. The 5-year overall (OS), disease-specific, and recurrence-free survival rates were 60, 76, and 66 %, respectively. There were 22 % low-, 34 % intermediate-, and 44 % high-risk patients. Patients who were p16-positive had better survival compared with p16-negative (OS, 74 vs. 44 %; p < .001). Similarly, low-risk group patients had a better survival compared with intermediate- and high-risk groups (OS, 76, 68, 45 %, respectively, p < .001). Independent predictors of survival in p16-negative patients included margin status, lymphovascular invasion, pN status, and extracapsular spread. In contrast, none of these were predictive in p16-positive patients. CONCLUSIONS: Surgically treated patients with p16-positive OPC have superior survival compared with p16-negative patients. Outcomes in p16-positive and p16-negative OPC are determined by different prognostic factors supporting the notion that these are very different diseases. These should be incorporated into future clinical trials design.
Authors: N Gopalakrishna Iyer; Leslie Kim; Iain J Nixon; Frank Palmer; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Head Neck Date: 2012-06-25 Impact factor: 3.147
Authors: David Mitchell; Riccardo Audisio; Garth Cruickshank; Stephen Cannon; Talvinder Gill; Andrew Hayes; Sean Kehoe; Jim McGuigan; Barry Powell; Nick Price; Nicholas Roland; Lynda Wyld Journal: BMJ Date: 2014-06-11
Authors: Jeremy Setton; Nicola Caria; Jonathan Romanyshyn; Lawrence Koutcher; Suzanne L Wolden; Michael J Zelefsky; Nicholas Rowan; Eric J Sherman; Matthew G Fury; David G Pfister; Richard J Wong; Jatin P Shah; Dennis H Kraus; Weiji Shi; Zhigang Zhang; Karen D Schupak; Daphna Y Gelblum; Shyam D Rao; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Somiah Siddiq; David Cartlidge; Sarah Stephen; Hans P Sathasivam; Hannah Fox; James O'Hara; David Meikle; Muhammad Shahid Iqbal; Charles G Kelly; Max Robinson; Vinidh Paleri Journal: Eur Arch Otorhinolaryngol Date: 2018-05-12 Impact factor: 2.503
Authors: Snjezana Dogan; Bin Xu; Sumit Middha; Chad M Vanderbilt; Anita S Bowman; Jocelyn Migliacci; Luc G T Morris; Venkatraman E Seshan; Ian Ganly Journal: Int J Cancer Date: 2019-05-30 Impact factor: 7.396
Authors: Linda X Yin; Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni M Rettig; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; David W Eisele; Carole Fakhry Journal: Laryngoscope Date: 2018-03-14 Impact factor: 3.325
Authors: B H Haughey; P Sinha; D Kallogjeri; R L Goldberg; J S Lewis; J F Piccirillo; R S Jackson; E J Moore; M Brandwein-Gensler; S J Magnuson; W R Carroll; T M Jones; M D Wilkie; A Lau; N S Upile; Jon Sheard; J Lancaster; S Tandon; M Robinson; D Husband; I Ganly; J P Shah; D M Brizel; B O'Sullivan; J A Ridge; W M Lydiatt Journal: Oral Oncol Date: 2016-09-23 Impact factor: 5.337
Authors: Ryan S Jackson; Parul Sinha; Joseph Zenga; Dorina Kallogjeri; Jasmina Suko; Eliot Martin; Eric J Moore; Bruce H Haughey Journal: Ann Surg Oncol Date: 2017-08-14 Impact factor: 5.344
Authors: Virginie Achim; Rachel K Bolognone; Andrew D Palmer; Donna J Graville; Tyler J Light; Ryan Li; Neil Gross; Peter E Andersen; Daniel Clayburgh Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-01-01 Impact factor: 6.223